title: Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm.
abstract: Although 5-fluorouracil (5-Fu) combination chemotherapy provides a satisfactory therapeutic response in patients with gestational trophoblastic neoplasms (GTNs), it has severe side effects. The current study analyzed the therapeutic effects and side effects of tegafur plus actinomycin D (Act-D) vs. 5-Fu plus Act-D for the treatment of GTNs based on controlled historical records. A total of 427 GTN cases that received tegafur and Act-D combination chemotherapy at the Second Xiangya Hospital of XiangYa Medical School between August 2003 and July 2013 were analyzed based on historical data. A total of 393 GTN cases that received 5-Fu plus Act-D between August 1993 and July 2003 at the same hospital were also analyzed, which constituted the control group. The therapeutic effects, toxicity and side effects after chemotherapy were compared between the groups. The overall response rate was 90.63% in the tegafur+Act-D group (tegafur group) and 92.37% in the 5-Fu+Act-D group (5-Fu group); these rates were not significantly different (P > 0.05). However, the incidence rates of myelosuppression (white blood cell decline), gastrointestinal reactions (nausea, vomiting, dental ulcer, and diarrhea), skin lesions and phlebitis were lower in the tegafur group than in the 5-Fu group (P < 0.05). The results of this study may provide useful data for the clinical application of tegafur in GTN treatment.
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Peng
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Yiling
authors.initials: Y
authors.lastname: Ding
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Yu
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Yali
authors.initials: Y
authors.lastname: Deng
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Weisi
authors.initials: W
authors.lastname: Lai
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Hongwen
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Xianqing
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Fan
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Ding
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Yilin
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Gynaecology & Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Guangshi
authors.initials: G
authors.lastname: Tao
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000737:chemistry* / Q000627:therapeutic use*; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy*; D006801:Humans; D011247:Pregnancy; D005641:Tegafur / Q000737:chemistry*
chemical_list: D005641:Tegafur; D003609:Dactinomycin; D005472:Fluorouracil